Clinical trial
A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and/or Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1/PD-L1 Antibody Therapy
NCT07141186 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and/or Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1/PD-L1 Antibody Therapy
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 1, 2025
- Completion date
- October 1, 2030
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cervical adenocarcinoma, cervical cancer, cervical cancer metastatic, cervical cancer recurrent, cervical cancer squamous cell